Pre-Conference Day

Tuesday, March 25, 2025

8:00 am Check-In & Coffee

8:55 am Chair’s Opening Remarks

Exploring Treg Biology to Better Understand Mechanisms of Action

9:00 am Clarifying Treg Function & Behavior to Enhance Therapeutic Development

Synopsis

  • Exploring the mechanisms involved in Treg generation
  • Examining the role of Tregs in controlling and reversing the inflammatory response to identify new therapeutic opportunities
  • Analyzing Treg behavior in different tissues to improve therapeutic efficacy in a variety of disease indications

9:30 am Analyzing the Q/E CD8+ Treg Pathway to Unlock Effective Clinical Applications

  • Hong Jiang Founder & Chief Scientific Officer, Avotres

Synopsis

  • Unravelling the unique mechanisms of the Q/E CD8+ Treg pathway
  • Detailing preclinical studies in animals and non-clinical ex vivo studies in humans
  • Analyzing safety and efficacy in newly completed phase I/II clinical trials in T1D
  • Exploring platforms of drug production and precision assay systems production platforms to ensure precision assay systems

10:00 am Morning Break & Networking

Examining the Top Challenges in Early-Stage Treg Discovery & Drug Development

11:00 am Roundtable Discussion: Exploring Strategies for Treg Tracking & Persistence Analysis

Synopsis

  • Discussing tracking techniques to aid in identifying Treg migration and longevity
  • Identifying opportunities for strategic optimization
  • Identifying effective Treg persistence and functionality biomarkers to enhance persistence analysis

11:45 am Roundtable Discussion: Reflecting Upon Key Obstacles in Preclinical Treg Research & Discovery

Synopsis

  • Exploring difficulties in effectively utilizing preclinical models in research
  • Addressing phenotypic uncertainties when identifying and characterizing Tregs to enhance accurate identification
  • Understanding Treg Plasticity between regulatory and inflammatory phenotypes to prevent the change of Tregs to T effector cells
  • Considering the specificity and selectivity limitations of Tregs therapies

12:30 pm Lunch Break & Networking

Highlighting New Ground-Breaking Data Exploring Tregs in the Brain

1:45 pm Unveiling Innovative Preclinical Meningeal Treg Research to Supercharge Therapeutic Development

Synopsis

  • Exploring the Treg population in the meninges in mouse and humans
  • Navigating Treg tolerogenic mechanism in the meninges
  • Discussing Treg/INF-γ regulation (inflammation)
  • Evaluating Treg/B-cells and plasma cell control
  • Discovering how meningeal Tregs change in neurodegenerative diseases (AD) in mouse and human

2:00 pm Utilizing Tissue-Specific Delivery of IL2 to Expand local Regulatory T-Cells

  • James Dooley Principal Research Associate, University of Cambridge, Department of Pathology

Synopsis

  • Leveraging tissue-specific IL2 delivery to expand local regulatory T-cells and reduce neuroinflammation, improving targeted therapeutic impact
  • Optimizing gene delivery methods for precise treatment of brain conditions, enhancing the safety and efficacy profile of therapies
  • Demonstrating proof of concept with preclinical models of neuroinflammation

2:30 pm End of Treg Biology Focus Day